M.B. Antsiferov, N.A. Demidov, M.A. Balberova, T.I. Safronova, O.A. Mishra
{"title":"根据体重指数和给药时间,甘精精100 U/ml和利西塞肽固定比例联合治疗2型糖尿病门诊患者的实际疗效:SOLO研究的事后分析","authors":"M.B. Antsiferov, N.A. Demidov, M.A. Balberova, T.I. Safronova, O.A. Mishra","doi":"10.33029/2304-9529-2023-12-3-12-19","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":485443,"journal":{"name":"Эндокринология. Новости, мнения, обучение","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real world effectiveness of fixed ratio combination of glargine 100 U/ml and lixisenatide therapy in outpatients with type 2 diabetes depending on body mass index and dose timing: post hoc analysis of the SOLO study\",\"authors\":\"M.B. Antsiferov, N.A. Demidov, M.A. Balberova, T.I. Safronova, O.A. Mishra\",\"doi\":\"10.33029/2304-9529-2023-12-3-12-19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":485443,\"journal\":{\"name\":\"Эндокринология. Новости, мнения, обучение\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Эндокринология. Новости, мнения, обучение\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33029/2304-9529-2023-12-3-12-19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Эндокринология. Новости, мнения, обучение","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33029/2304-9529-2023-12-3-12-19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real world effectiveness of fixed ratio combination of glargine 100 U/ml and lixisenatide therapy in outpatients with type 2 diabetes depending on body mass index and dose timing: post hoc analysis of the SOLO study